One-Liner
A longitudinal platform connecting rare-disease patients with pre-approval windows to clinical trial sponsors, monetized by pharma sponsor access to curated patient cohorts.
AI Thinking Process
Thread 4: LMNA-DCM / FSHD / DIPG pre-approval navigator. Longitudinal monthly check-ins for 3 years. Therapy-readiness score. Pharma sponsor pays for curated cohort at trial time; patient uses free. Rocket RP-A501 Phase 2 readout 2026, potential BLA 2029-2030.
PatientsLikeMe (UnitedHealth), Antidote (one-shot match), RareConnect (EURORDIS), Ciitizen/Labcorp (records aggregation), Xcures (oncology). Closest: Ciitizen. None do longitudinal readiness navigation with pharma-sponsor monetization.
Disease population only ~10K LMNA-DCM. Single-disease fails same as Sjögren's one-shot from 2026-04-17 session. Must be multi-disease platform. Cardiologist adoption risk.
Survived at 45% under caution flag: must recast as multi-disease platform. Single-disease LMNA alone repeats Sjögren's failure mode.
Allstripes raised Series C ~$50M in 2024 explicitly for multi-disease platform expansion. Direct competitive — patient base, pharma relationships, data pipeline all in place. Adding therapy-readiness score is a one-quarter roadmap item.
DIPG Phase 3 claim overstated — mostly Phase 2s exist. Multi-disease thesis weakens from 3 clean windows to 2.
FEATURE gate failed: Allstripes Series C 2024 for multi-disease expansion. One quarter to add therapy-readiness score. Standalone product would not survive. Killed in deepening.
Kill Reason
Allstripes (formerly RDMD) raised a Series C of approximately $50M in 2024 explicitly for multi-disease platform expansion, with an existing patient base, pharma-sponsor relationships, and a natural-history data pipeline. Adding a 'therapy-readiness score' feature is a one-quarter roadmap item for them. A standalone product would not survive in the same market. DIPG Phase 3 claim in Pass 1 was also overstated — reducing the multi-disease thesis from 3 clean windows to 2.
Risk Analysis
Risk analysis available for latest engine ideas.
What do you think?
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.